Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590717 | 0.86 | CHRNA7 (0.49) | SLC6A4MAOAMAOBCYP2C9HTR1A | |
| SCHEMBL11252021 | 0.83 | LMNA (0.44) | SLC6A4CYP1A2CYP3A4CYP2C9HTR1A | |
| SCHEMBL11471494 | 0.83 | HTR1A (0.46) | SLC6A4HTR1AHTR3AALDH1A1LMNA | |
| SCHEMBL4437147 | 0.82 | ALDH1A1 (0.46) | SLC6A4CYP1A2CYP3A4CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4556353 | 0.80 | ALDH1A1 (0.44) | SLC6A4CYP1A2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6937792 | 0.80 | MEN1 (0.65) | SLC6A4HTR1AHTR3AMEN1KMT2A | |
| SCHEMBL11487186 | 0.79 | AR (0.42) | SLC6A4HTR1AHTR3AMEN1KMT2A | |
| SCHEMBL11705626 | 0.79 | SLC6A4 (0.65) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5659555 | 0.79 | MAP2K2 (0.46) | SLC6A4CYP2C9ALDH1A1LMNAMEN1 | |
| SCHEMBL11760701 | 0.78 | HTR1A (0.47) | SLC6A4MAOAMAOBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0013424-B1 | SPIRO(DIBENZO(B,F)THIEPINE-PIPERIDINES), INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-11-17 | — | — | EP | disclosed |
| EP-0013424-A1 | Spiro(dibenzo(b,f)thiepine-piperidines), intermediate products for their preparation and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-07-23 | — | — | EP | disclosed |
| US-4198420-A | Spiro[dibenz(b,f)thiepin-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1980-04-15 | — | — | US | disclosed |
| US-4198419-A | Phenylthiophenylpiperidines | AMERICAN HOECHST CORPORATION (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | SLC6A4 84/4885MAOA 29/4885MAOB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.